Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT03631017
PHASE1/PHASE2

Imaging With a PET Agent for Detection of Cancers of the Head and Neck

Sponsor: Memorial Sloan Kettering Cancer Center

View on ClinicalTrials.gov

Summary

The purpose of this study is to test the safety of a study drug called PARPi-FL. This drug has been tested in animals but not yet in people. The purpose of this study is to test if a PARPi-FL scan can be used to take pictures of head and neck cancer. The usual approach to imaging this cancer includes several different imaging scans, including x-rays, CT (computed tomography), MRI (magnetic resonance imaging), and PET (positron emission tomography). These tests take pictures of the cancer.

Official title: Safety, Biodistribution and Radiation Dosimetry of [18F]PARPi

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

12

Start Date

2018-08-10

Completion Date

2026-08

Last Updated

2025-09-03

Healthy Volunteers

No

Interventions

DRUG

[18F]- PARPi

injection of a microdose (\< 100 ug) of \[18F\]- PARPi

DIAGNOSTIC_TEST

PET/CT Scans

Patients will be injected with approximately 10 mCi of \[18F\]PARPi and a dynamic PET scan of will be acquired for approximately 30 minutes. A second body PET/CT scan will be started approximately 60 min post injection, and a third PET/CT scan will be started at approximately 120 min post injection. The first (dynamic) and the second (body) PET/CT scan will use "ultra -low dose" CT scan for attenuation correction. The last PET/CT scan will be performed with the investigator's regular clinical low-dose CT settings.

Locations (1)

Memorial Sloan Kettering Cancer Center

New York, New York, United States